Reata Pharmaceuticals Inc (NASDAQ:RETA) CFO Jason Douglas Wilson sold 20,000 shares of the company’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $72.04, for a total transaction of $1,440,800.00. Following the completion of the sale, the chief financial officer now directly owns 20,000 shares in the company, valued at $1,440,800. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

RETA opened at $72.49 on Friday. Reata Pharmaceuticals Inc has a 1 year low of $19.31 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 2.10, a quick ratio of 6.04 and a current ratio of 6.04. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -36.43 and a beta of 2.84.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($1.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.79) by ($0.28). The firm had revenue of $5.18 million during the quarter, compared to analyst estimates of $9.50 million. Sell-side analysts predict that Reata Pharmaceuticals Inc will post -3.08 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its position in shares of Reata Pharmaceuticals by 276.8% in the third quarter. Tower Research Capital LLC TRC now owns 1,398 shares of the company’s stock valued at $114,000 after buying an additional 1,027 shares in the last quarter. Lee Financial Co purchased a new stake in shares of Reata Pharmaceuticals during the third quarter worth approximately $128,000. Cubist Systematic Strategies LLC purchased a new stake in Reata Pharmaceuticals in the 2nd quarter valued at $154,000. First Mercantile Trust Co. purchased a new stake in Reata Pharmaceuticals in the 3rd quarter valued at $167,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in Reata Pharmaceuticals by 53.2% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 5,460 shares of the company’s stock valued at $191,000 after buying an additional 1,897 shares in the last quarter. 52.85% of the stock is owned by institutional investors.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, September 25th. LADENBURG THALM/SH SH restated a “buy” rating and set a $133.00 target price on shares of Reata Pharmaceuticals in a research note on Wednesday, September 26th. Leerink Swann reiterated an “outperform” rating and issued a $139.00 price objective (up previously from $116.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, September 25th. BidaskClub lowered shares of Reata Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, September 28th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $100.00 target price on shares of Reata Pharmaceuticals in a report on Monday, October 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $100.33.

ILLEGAL ACTIVITY WARNING: This story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://theolympiareport.com/2019/01/11/jason-douglas-wilson-sells-20000-shares-of-reata-pharmaceuticals-inc-reta-stock.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.